Article
Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib.
Anti-cancer drugs - 1 Apr 2015
Gamba Sebastian, Camaj Peter, Heinemann Volker, Laubender Rüdiger P, Wang Yan, Zhao Yue, Stintzing Sebastian, Giessen Clemens, Boeck Stefan, Haertl Christoph, Bruns Christiane J, Modest Dominik P
Abstract excerpt
The aim of this study was to investigate the impact of different KRAS mutations on the inhibitory potential of afatinib and gefitinib in SW48 colorectal cancer cells. The influence of afatinib/gefitinib on cell viability and cell cycle was evaluated in isogenic SW48 KRAS wild-type/mutant cells. Protein levels of phosphorylated/total EGFR, HER-2, HER-3, ERK, and AKT were compared between treated/untreated samples...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.